PharmNovo raises SEK 67 million to take neuropathic pain drug candidate into clinical trial
PharmNovo AB, a Swedish pharmaceutical company developing drugs for neuropathic pain, so-called nerve pain, has completed a share issue of SEK 67 million led by the investor syndicate Sciety. Karolinska Development AB also participated in the share issue. The capital will be used to produce the drug substance, implement a clinical phase I study, and continue the company's development.Nerve pain affects almost ten percent of the population in Europe and the United States and significantly impairs people's quality of life. The drug candidate PN6047 from PharmNovo is an entirely new type of